FORM OF LOCK-UP AGREEMENTLock-Up Agreement • August 3rd, 2017 • Alpine ImmunoSciences, L.P. • Pharmaceutical preparations • Delaware
The undersigned signatory of this lock-up agreement (this “Lock-Up Agreement”) understands that Nivalis Therapeutics, Inc., a Delaware corporation (“Nivalis”) has entered into an Agreement and Plan of Merger and Reorganization, dated as of April 18, 2017 (as the same may be amended from time to time, the “Merger Agreement”) with Nautilus Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Nivalis, and Alpine Immune Sciences, Inc., a Delaware corporation. Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Merger Agreement.
JOINT FILING AGREEMENTJoint Filing Agreement • August 3rd, 2017 • Alpine ImmunoSciences, L.P. • Pharmaceutical preparations
The undersigned hereby agree that the statement on Schedule 13D with respect to the common stock, $0.001 par value per share of Alpine Immune Sciences, Inc. dated as of August 3, 2017 is, and any amendments thereto (including amendments on schedule 13G) signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.
JOINT FILING AGREEMENTJoint Filing Agreement • January 23rd, 2019 • Alpine ImmunoSciences, L.P. • Pharmaceutical preparations
The undersigned hereby agree that the statement on Schedule 13D with respect to the common stock, $0.001 par value per share of Alpine Immune Sciences, Inc. dated as of January 22, 2019 is, and any amendments thereto (including amendments on schedule 13G) signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.
